We are live on ! Find out more
ICCM icon

IceCure Medical

0.7710 USD
-0.0718
8.52%
At close Updated Nov 3, 4:00 PM EST
Pre-market
After hours
0.7714
+0.0004
0.05%
1 day
-8.52%
5 days
-21.33%
1 month
-49.94%
3 months
-72.27%
6 months
-91.25%
Year to date
-95.92%
1 year
-96.47%
5 years
-99.67%
10 years
-99.76%
 

About: Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Employees: 66

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 7.7%
Neutral 92.3%
Negative 0%
Neutral
PRNewsWire
8 days ago
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
First patient enrolled and treated at West Cancer Center in Tennessee, USA CAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has successfully completed the treatment of the first patient in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer.
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
Neutral
PRNewsWire
15 days ago
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
CAESAREA, Israel, Oct. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer.
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
Neutral
PRNewsWire
22 days ago
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
Scientific presentations, research posters and clinical workshops featured ProSense® breast cancer cryoablation and highlighted strong physician engagement across Europe CAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, announced today that ProSense® breast cancer cryoablation was featured in multiple scientific presentations, research posters and physician workshops at the European Society of Breast Imaging ("EUSOBI") Annual Scientific Meeting 2026, held in Maastricht, the Netherlands.
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
Neutral
PRNewsWire
29 days ago
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
CAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the addition of Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new U.S. clinical site for its post-marketing study (the "ChoICE Study") evaluating the use of ProSense® cryoablation in the local treatment of low-risk breast cancer.
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
Positive
Zacks Investment Research
1 month ago
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
IceCure Secures China NMPA Approval for ProSense Cryoablation System
Neutral
PRNewsWire
1 month ago
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd.
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
Neutral
PRNewsWire
2 months ago
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of IceCure's ProSense® cryoablation systems in the Netherlands for breast cancer and interventional oncology.
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Neutral
PRNewsWire
2 months ago
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the Company's post-marketing study ("ChoICE Study") for ProSense® cryoablation in the local treatment of low-risk breast cancer.
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Neutral
PRNewsWire
2 months ago
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastases CAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation.
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
Neutral
Seeking Alpha
2 months ago
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™